NCT00303251View on ClinicalTrials.gov

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2009

Conditions
Melanoma
Interventions
DRUG

TKI258

Trial Locations (3)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

40202

James Graham Brown Cancer Center, Louisville

77030

MD Anderson Cancer, Houston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY